TenderlineUK
Procurement Intelligence
Official OCDSSearch

Retender radar: UK public contracts ending soon

Every contract in the catalogue with a published end date in the future, one row per contract (lot). A contract ending is a procurement starting, unless the buyer uses a published extension option, which the row shows. Frameworks and DPS are marked: what ends there is the vehicle, not one supplier’s contract.

Contracts ending in the next 12 months

Page 36 · 50 contracts on this page · more available

SortEnding soonestLargest contract valueLargest annual run-rate
FrameworkClear all

1,000+ contracts

  1. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Arcadia Pharma Ltd T/A Arcadia Medical

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  2. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Kyowa Kirin Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  3. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Waymade PLC

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  4. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Medreich PLC

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  5. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Dr Falk Pharma UK Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  6. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Lupin Healthcare UK Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  7. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Crescent Pharma Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  8. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Derma UK

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  9. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Strides Pharma Uk LTD

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  10. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Phoenix Lab

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  11. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: DRUGSRUS LTD

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  12. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Aspen Pharmacare UK Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  13. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Scope Ophthalmics Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  14. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: AOP Orphan Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  15. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Martindale Pharma

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  16. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Bayer Plc

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  17. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Krka UK ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  18. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Relonchem Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  19. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Ferring Pharmaceuticals Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  20. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Torrent Pharma UK Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  21. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: JCSH Pharma Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  22. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Lundbeck Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  23. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Takeda UK Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  24. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Reckitt Benckiser

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  25. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Strandhaven Ltd t/a Somex Pharma

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  26. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Wockhardt UK Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  27. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Synchrony Pharma Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  28. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Brown and Burk UK Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  29. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Tillomed Laboratories Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  30. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Galen Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  31. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Necessity Supplies Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  32. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Medley Pharma Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  33. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Manx Healthcare Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  34. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: LogixX Pharma Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  35. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Ascend Laboratories UK Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  36. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Rivopharm UK Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  37. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Zentiva Pharma UK Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  38. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Norgine Pharmaceuticals Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  39. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Cipla

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  40. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Genesis Pharmaceuticals Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  41. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Focus Pharmaceuticals Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  42. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Beaumont Pharma Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  43. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Typharm Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  44. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Oralieve UK Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  45. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Clydesdale Pharma ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  46. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: RPH Pharmaceuticals AB

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  47. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Uni Health Distribution Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  48. Ends · in 230 daysFramework re-let

    Wave 14c - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Ipca Laboratories UK Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-040d4d
  49. Ends · in 230 daysFramework re-let

    Wave 15a - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Viatris UK Healthcare Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-046a2f
  50. Ends · in 230 daysFramework re-let

    Wave 15a - Orals (plus non-parenteral) Products (all regions)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Scope Ophthalmics Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 31 May 2027 · start not published
    Reference
    ocds-h6vhtk-046a2f
How to read the radar
  • End date is the contract period end the buyer published on the notice. Contracts without an end date are not on the radar.
  • Extension option means the notice publishes a renewal or option clause; the buyer may extend instead of retendering. Hide them to see contracts that must be re-procured.
  • Incumbent is the supplier named on the award behind the contract. A panel (several suppliers on one award) is shown as a panel; no single incumbent is invented.
  • Annual run-rate = published GBP value ÷ published term, only for a single supplier, a term of six months or more and a plain contract (not a framework or DPS ceiling).
  • Counts are exact for the time-horizon and sector filters. With other filters, a result above 1,000 contracts shows as “1,000+”.
  • Source. Official UK procurement notices, reused under the Open Government Licence v3.0; the radar is rebuilt nightly. How we count: methodology.